依鲁替尼治疗慢性淋巴细胞白血病伴第二肿瘤:两例报告及文献复习

Pub Date : 2020-03-25 DOI:10.3760/CMA.J.CN115356-20190828-00168

Qian Yang, Jun-xia Huang, S. Nie, Tianlan Li, Yan Gao, Xueshen Yan, Shanshan Liu, Chunxia Mao, Jingjing Zhou, Yujie Xu, Fanjun Meng, Xianqi Feng

{"title":"依鲁替尼治疗慢性淋巴细胞白血病伴第二肿瘤:两例报告及文献复习","authors":"Qian Yang, Jun-xia Huang, S. Nie, Tianlan Li, Yan Gao, Xueshen Yan, Shanshan Liu, Chunxia Mao, Jingjing Zhou, Yujie Xu, Fanjun Meng, Xianqi Feng","doi":"10.3760/CMA.J.CN115356-20190828-00168","DOIUrl":null,"url":null,"abstract":"目的 \n提高对慢性淋巴细胞白血病（CLL）合并第二肿瘤的认识。 \n \n \n方法 \n报道青岛大学附属医院2例给予伊布替尼治疗的CLL患者，分别合并腹腔消化道来源腺癌和鳞状细胞癌，并复习相关文献。 \n \n \n结果 \n2例CLL患者在确诊后，在给予伊布替尼过程中合并第二肿瘤。 \n \n \n结论 \n应积极评估CLL病情，严格遵守CLL治疗指征标准，早期发现治疗第二肿瘤。","PeriodicalId":59994,"journal":{"name":"","volume":"29 1","pages":"185-187"},"PeriodicalIF":0.0,"publicationDate":"2020-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ibrutinib in treatment of chronic lymphocytic leukemia with a second tumor: report of two cases and review of literature\",\"authors\":\"Qian Yang, Jun-xia Huang, S. Nie, Tianlan Li, Yan Gao, Xueshen Yan, Shanshan Liu, Chunxia Mao, Jingjing Zhou, Yujie Xu, Fanjun Meng, Xianqi Feng\",\"doi\":\"10.3760/CMA.J.CN115356-20190828-00168\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"目的 \\n提高对慢性淋巴细胞白血病（CLL）合并第二肿瘤的认识。 \\n \\n \\n方法 \\n报道青岛大学附属医院2例给予伊布替尼治疗的CLL患者，分别合并腹腔消化道来源腺癌和鳞状细胞癌，并复习相关文献。 \\n \\n \\n结果 \\n2例CLL患者在确诊后，在给予伊布替尼过程中合并第二肿瘤。 \\n \\n \\n结论 \\n应积极评估CLL病情，严格遵守CLL治疗指征标准，早期发现治疗第二肿瘤。\",\"PeriodicalId\":59994,\"journal\":{\"name\":\"\",\"volume\":\"29 1\",\"pages\":\"185-187\"},\"PeriodicalIF\":0.0,\"publicationDate\":\"2020-03-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.CN115356-20190828-00168\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.CN115356-20190828-00168","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

Objective: To improve the understanding of chronic lymphocytic leukemia (CLL) with secondary tumors. Method: Two CLL patients treated with ibutinib at the Affiliated Hospital of Qingdao University were reported, who were complicated with abdominal gastrointestinal adenocarcinoma and squamous cell carcinoma, respectively. Relevant literature was reviewed. As a result, two CLL patients were diagnosed with a second tumor during the administration of ibutinib. Conclusion: The condition of CLL should be actively evaluated, strict adherence to CLL treatment indication standards, and early detection and treatment of secondary tumors.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Ibrutinib in treatment of chronic lymphocytic leukemia with a second tumor: report of two cases and review of literature

目的提高对慢性淋巴细胞白血病（CLL）合并第二肿瘤的认识。方法报道青岛大学附属医院2例给予伊布替尼治疗的CLL患者，分别合并腹腔消化道来源腺癌和鳞状细胞癌，并复习相关文献。结果 2例CLL患者在确诊后，在给予伊布替尼过程中合并第二肿瘤。结论应积极评估CLL病情，严格遵守CLL治疗指征标准，早期发现治疗第二肿瘤。

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助